DECNUPAZ™(pivekimab sunirine-pvzy), FDA‑Approved for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Exclusively Available at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy provider for DECNUPAZ, an intravenous therapy approved for patients with blastic plasmacytoid dendritic cell neoplasm.